AcQBlate FORCE: the first and only force sensing ablation catheter with a gold tip electrode. Credit: Acutus Medical.

Acutus Medical has completed patient enrolment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial.

The trial aims to assess the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system for treating right atrial typical flutter.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Right atrial flutter is a disorder that generates rapid electrical signals, causing the muscles in the heart’s upper chamber (atria) to contract quickly.

This can lead to an increase in heartbeat and trigger other symptoms, such as chest pain, shortness of breath, dizziness and fainting. Additionally, a continuous rapid heartbeat may increase stress on the heart, thereby increasing stroke risk.

Catheter ablation is a common procedure to treat right atrial flutter disorder.

The AcQBlate FORCE solution enables physicians to check the amount of contact force being applied to the heart during ablations in real-time.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to the company, studies have indicated that real-time contact force information facilitates safe and effective therapy, as well as helps to improve patient outcomes.

The trial enrolled a total of 110 patients at 21 sites globally. The final patient follow-up is expected next month.

Acutus Medical interim CEO and chief financial officer David Roman said: “Completing enrolment in the AcQForce Flutter trial represents a significant advancement in our journey to enter the US with a therapeutic technology for the treatment of atrial flutter.

“Acutus has a strong history of partnering with physicians to bring innovative technology to the market to treat atrial arrhythmias, and we are thankful to our clinical trial sites, specifically the dedication and commitment of investigators and their staff, and to our clinical team for their collaboration in reaching this milestone.”

The complete AcQBlate FORCE sensing ablation catheter and system already received full CE Mark in 2020 and is currently available in Europe.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact